# Urogen Pharma Ltd. (URGN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.40B  
**Price:** $29.00 (+3.57%)

> UroGen Pharma Ltd. is an Israel-based biopharmaceutical company specializing in innovative treatments for urological cancers and diseases. The company develops therapies using its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release platform that enhances drug delivery directly to targeted tissues in the urinary tract. Key FDA-approved products include Jelmyto, a mitomycin-based formulation for low-grade upper tract urothelial cancer, and Zusduri, designed for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances a pipeline of product candidates like MitoGel (UGN-101) and VesiGel (UGN-102), focusing on chemotherapy agents such as mitomycin C for various bladder and upper tract cancers. This technology addresses limitations of traditional treatments by enabling localized, prolonged exposure while minimizing systemic side effects. Operating in the pharmaceuticals and biotechnology sector, UroGen Pharma Ltd. plays a vital role in uro-oncology by providing non-surgical alternatives and expanding patient access to advanced bladder cancer therapies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $110M | $97M | -$125M | -$153M | — |
| 2024 | $90M | $82M | -$97M | -$127M | — |
| 2023 | $83M | $73M | -$66M | -$102M | — |
| 2022 | $64M | $57M | -$79M | -$110M | — |
| 2021 | $48M | $43M | -$92M | -$111M | — |
| 2020 | $12M | $11M | -$127M | -$128M | — |
| 2019 | $18,000 | $18,000 | -$109M | -$105M | — |
| 2018 | $1M | -$675,000 | -$77M | -$76M | — |
| 2017 | $8M | $8M | -$20M | -$20M | — |
| 2016 | $18M | $18M | $798,000 | -$2M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $200M | $306M | -$105M | $111M | $125M |
| 2024 | $286M | $295M | -$9M | $172M | $122M |
| 2023 | $178M | $244M | -$65M | $95M | $99M |
| 2022 | $136M | $225M | -$89M | $55M | $98M |
| 2021 | $120M | $111M | $8M | $44M | — |
| 2020 | $122M | $26M | $96M | $53M | — |
| 2019 | $202M | $22M | $180M | $50M | — |
| 2018 | $104M | $13M | $90M | $101M | — |
| 2017 | $76M | $7M | $69M | $37M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$162M | $289,000 | -$163M |
| 2024 | -$97M | $295,000 | -$97M |
| 2023 | -$76M | $194,000 | -$77M |
| 2022 | -$88M | $254,000 | -$88M |
| 2021 | -$85M | $752,000 | -$86M |
| 2020 | -$106M | $1M | -$107M |
| 2019 | -$71M | $325,000 | -$71M |
| 2018 | -$37M | $560,000 | -$38M |
| 2017 | -$10M | $271,000 | -$10M |
| 2016 | $4M | $695,000 | $3M |

Source: [CompaniesByCap](https://companiesbycap.com/company/URGN)